Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Duration of PFS in the patient subgroup with MET amplification

Gorde:

Xehetasun bibliografikoak
Egile nagusia:	Chong Kin Liam (15331321) (author)
Beste egile batzuk:	Azura Rozila Ahmad (15331324) (author), Te-Chun Hsia (15331327) (author), Jianying Zhou (15331330) (author), Dong-Wan Kim (15036467) (author), Ross Andrew Soo (15331333) (author), Ying Cheng (15331336) (author), Shun Lu (15331339) (author), Sang Won Shin (15331342) (author), James Chih-Hsin Yang (15048002) (author), Yiping Zhang (15331345) (author), Jun Zhao (11571833) (author), Karin Berghoff (15331348) (author), Rolf Bruns (15331351) (author), Andreas Johne (15331354) (author), Yi-Long Wu (11678896) (author)
Argitaratua:	2025
Gaiak:	Cancer Therapeutic Research and Development Clinical Research and Trials Chemotherapy Clinical Trial Results Clinical-Stage Research Drug Resistance Lung Cancer Precision Medicine Small Molecule Agents
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis